Phase 3 Readout
CRNX: Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Trial of Dalargin for the Prevention of Postoperative
December 20, 2026 · dalargin. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 20, 2026
- Company
- Crinetics Pharmaceuticals, Inc. (CRNX)
- Drug
- dalargin
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Trial of Dalargin for the Prevention of Postoperative
- Drug
- dalargin
- Indication
- Postoperative Complications; Multiple Organ Failure; Abdominal Surgery